Published: 16 January 2020
Author(s): John R. Hurst, Neil Skolnik, Gerald J. Hansen, Antonio Anzueto, Gavin C. Donaldson, Mark T. Dransfield, Precil Varghese
Issue: January 2020
Section: Review Article

Chronic obstructive pulmonary disease (COPD) was the third leading cause of mortality in 2016 and was responsible for an estimated 3 million deaths worldwide that year, representing a vast global problem [1]. COPD exacerbations are responsible for the majority of the substantial burden that COPD places on healthcare systems [2,3]. In the USA, the annual cost of COPD management has been shown to increase proportionally with the number of COPD exacerbations, with COPD-related costs, including pharmacy claims for COPD treatments, more than six times higher in patients experiencing frequent (≥2/year) exacerbations ($4361) compared with those who had none ($644) [4].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.